UNITUXIN
Total Payments
$3.5M
Transactions
646
Doctors
239
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $82,910 | 51 | 32 |
| 2023 | $264,591 | 18 | 7 |
| 2022 | $617,677 | 38 | 18 |
| 2021 | $165,106 | 69 | 28 |
| 2020 | $774,117 | 134 | 19 |
| 2018 | $1.5M | 284 | 136 |
| 2017 | $137,324 | 52 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 344 | 99.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,040 | 121 | 0.4% |
| Food and Beverage | $6,440 | 128 | 0.2% |
| Education | $560.00 | 53 | 0.0% |
Payments by Type
Research
$3.5M
344 transactions
General
$21,041
302 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE IIIII STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | United Therapeutics Corporation | $967,214 | 2 |
| A PHASE I STUDY OF 131I-MIBG WITH DINUTUXIMAB +/- VORINOSTAT FOR RELAPSED/REFRACTORY NEUROBLASTOMA | United Therapeutics Corporation | $408,186 | 0 |
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | United Therapeutics Corporation | $362,480 | 2 |
| A PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS EXPANDED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY OF RELAPSED REFRACTORY NEUROBLASTOMA WITH DINUTUXIMAB +/- LENALIDOMIDE | United Therapeutics Corporation | $283,318 | 0 |
| POLYAMINE DEPLETION BY DFMO TO REDUCE ALLODYNIA AND IMPROVE EFFICACY OF DINUTUXIMAB THERAPY | United Therapeutics Corporation | $165,546 | 0 |
| GD2 THERAPY FOR BREAST CANCER PREVENTION | United Therapeutics Corporation | $161,160 | 0 |
| PHASE 2 ALLOGENIC NK CELLS IN COMBINATION WITH IRINOTECAN, TEMOZOLOMIDE, DINUTUXIMABAND GM-CSF. | United Therapeutics Corporation | $150,000 | 0 |
| RAPID Feasibility Study: A Pilot Study for the Rapid Infusion of Dinutuximab | United Therapeutics Corporation | $146,158 | 0 |
| POST-MARKETING ASSESSMENT OF IMMUNOGENICITY AND SAFETY OF UNITUXIN IN HIGH-RISK NEUROBLASTOMA PATIENTS | United Therapeutics Corporation | $134,609 | 0 |
| ASSESSING GD2 EXSPRESSION IN RECURRENT NEUROBLASTOMA | United Therapeutics Corporation | $105,811 | 0 |
| IMMUNOTHERAPY OF RELAPSED NEUROBLASTOMA WITH EXPANDED NK CELLS LENALIDOMIDE AND CH14.18. | United Therapeutics Corporation | $93,374 | 0 |
| RAPID FEASIBILITY STUDY: A PILOT STUDY FOR THE RAPID INFUSION OF DINUTUXIMAB | United Therapeutics Corporation | $80,270 | 0 |
| A PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS EXPANDED NATURAL KILLER NK CELLS FOR IMMUNOTHERAPY OF RELAPSED REFRACTORY NEUROBLASTOMA WITH DINUTUXIMAB - LENALIDOMIDE | United Therapeutics Corporation | $54,327 | 0 |
| A SAFETY STUDY OF INTRAVENOUS INFUSION OF BONE MARROW MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES (UNEX-42) IN PRETERM NEONATES AT HIGH RISK FOR BRONCHOPULMONARY DYSPLASIA | United Therapeutics Corporation | $31,570 | 0 |
| CONTROLLED RELEASE DELIVERY OF ANTI-GD2 ANTIBODY | United Therapeutics Corporation | $24,375 | 0 |
| A PHASE II RANDOMIZED TRIAL OF IRINOTECAN/TEMOZOLOMIDE WITH TEMSIROLIMUS (NSC# 683864) OR CHIMERIC 14.18 ANTIBODY (CH14.18) (NSC# 764038) IN CHILDREN WITH REFRACTORY, RELAPSED OR PROGRESSIVE NEUROBLASTOMA | United Therapeutics Corporation | $16,711 | 0 |
| Effect of indocyanine green-labeled anti-GD2 antibody (ICG-dinutuximab) on gross total resection of GD2-positive neuroblastoma in an orthotopic murine model | United Therapeutics Corporation | $13,585 | 0 |
| EFFECT OF INDOCYANINE GREEN-LABELED ANTI-GD2 ANTIBODY (ICG-DINUTUXIMAB) ON GROSS TOTAL RESECTION OF GD2-POSITIVE NEUROBLASTOMA IN AN ORTHOTOPIC MURINE MODEL | United Therapeutics Corporation | $13,585 | 0 |
| Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGF?i NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | United Therapeutics Corporation | $6,839 | 0 |
| A POST-MARKETING STUDY TO FURTHER ASSESS THE IMMUNOGENICITY AND SAFETY OF UNITUXIN IN HIGH-RISK NEUROBLASTOMA PATIENTS | United Therapeutics Corporation | $6,507 | 0 |
Top Doctors Receiving Payments for UNITUXIN — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Kissimmee, FL | $100.00 | 1 |
| , M.D | Internal Medicine | Peabody, MA | $100.00 | 1 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $100.00 | 1 |
| , M.D | Internal Medicine | Cedar Park, TX | $100.00 | 1 |
| , MD | Hematology & Oncology | Saint Cloud, MN | $100.00 | 1 |
| , MD | Hematology & Oncology | Philadelphia, PA | $100.00 | 1 |
| , M.D | Specialist | Lake Havasu City, AZ | $100.00 | 1 |
| , MD | Internal Medicine | Cameron Park, CA | $100.00 | 1 |
| , M.D | Hematology & Oncology | Royal Oak, MI | $100.00 | 1 |
| , MD | Pediatrics | Des Moines, IA | $100.00 | 1 |
| , M.D | Medical Oncology | Santa Rosa, CA | $100.00 | 1 |
| , MD | Hematology & Oncology | Portsmouth, OH | $100.00 | 1 |
| , MD | Specialist | E Setauket, NY | $100.00 | 1 |
| , MD | Medical Oncology | Waterloo, IA | $100.00 | 1 |
| Ravi Verma | — | Parma, OH | $100.00 | 1 |
| , M.D | Internal Medicine | Goshen, IN | $100.00 | 1 |
| , MD | Internal Medicine | Columbus, OH | $100.00 | 1 |
| , M.D., PH.D | Medical Oncology | Gilbert, AZ | $100.00 | 1 |
| , MD | Hematology & Oncology | Los Angeles, CA | $100.00 | 1 |
| , M.D | Hematology & Oncology | Munster, IN | $100.00 | 1 |
| , D.O | Medical Oncology | Union, NJ | $100.00 | 1 |
| , M.D | Hematology & Oncology | Akron, OH | $100.00 | 1 |
| , M.D./PH.D | Internal Medicine | Scottsdale, AZ | $100.00 | 1 |
| , M.D | Surgery | Willingboro, NJ | $100.00 | 1 |
| , M.D | Internal Medicine | Cincinnati, OH | $100.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 239
- Transactions 646
About UNITUXIN
UNITUXIN is a drug associated with $3.5M in payments to 239 healthcare providers, recorded across 646 transactions in the CMS Open Payments database. The primary manufacturer is United Therapeutics Corporation.
Payment data is available from 2017 to 2024. In 2024, $82,910 was paid across 51 transactions to 32 doctors.
The most common payment nature for UNITUXIN is "Unspecified" ($3.5M, 99.4% of total).
UNITUXIN is associated with 20 research studies, including "A TWO-PART OPEN-LABEL RANDOMIZED PHASE IIIII STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER" ($967,214).